Malé, Maldives – Oxford-AstraZeneca licensed, Serum Institute of India (SII) manufactured Covishield vaccine is approved by the Maldives Food and Drug Authority to be used in Maldives on the 26th January 2021.
The approval to use this vaccine in Maldives has been granted by this Authority after thorough review of technical aspects with regards to the vaccination, as well as with consideration of the recommendation made by the National Pharmaceutical Board, which offers technical expertise recommendations to the authority.
Maldives Food and Drug Authority (MFDA)
The current decision is taken under the “Restricted Use in Emergency Situations” protocol, after thorough vetting of the jab. The formulation and composition of the vaccine was investigated and accredited literature from international sources were scrutinized by the authorities.
The vaccine is currently approved to be used for adults over 18 years of age. While the Ministry of Health and Health Protection Agency (HPA) acknowledge the potential reactions to the vaccine, the inoculation process will be closely monitored, according to a statement released by the MFDA.
This is the first Covid-19 vaccine being approved in Maldives since the pandemic began and World Health Organization (WHO) guidelines were followed before the approval.
